Prevention of the phencyclidine-induced impairment in novel object recognition in female rats by Co-administration of lurasidone or tandospirone, a 5-HT 1A partial agonist

Neuropsychopharmacology

Volumn 37, Issue 10, 2012, Pages 2175-2183

  Horiguchi, Masakuni ^a,b,c   Hannaway, Kayleen E ^a   Adelekun, Adesewa E ^a   Jayathilake, Karu ^a,b   Meltzer, Herbert Y ^a,b  

^a VANDERBILT UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

cognitive impairment; lurasidone; novel object recognition; phencyclidine; prevention; tandospirone

Indexed keywords

HALOPERIDOL; LURASIDONE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; PARTIAL AGONIST; PHENCYCLIDINE; PIMAVANSERIN; SEROTONIN 1A RECEPTOR; TANDOSPIRONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; FEMALE; MEMORY DISORDER; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; RAT; RECOGNITION; VISUAL MEMORY;

ANIMALS; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; FEMALE; HALOPERIDOL; ISOINDOLES; PHENCYCLIDINE; PIPERAZINES; PIPERIDINES; PYRIDINES; PYRIMIDINES; RATS; RATS, LONG-EVANS; RECEPTORS, DOPAMINE D2; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SEROTONIN 5-HT1 RECEPTOR ANTAGONISTS; SEROTONIN 5-HT2 RECEPTOR AGONISTS; THIAZOLES; UREA;

EID: 84865259333     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2012.64     Document Type: Article

References (76)

1. Abdul-Monim Z, Neill JC, Reynolds GP (2007). Sub-chronic psychotomimetic phencyclidine induces deficits in reversal learning and alterations in parvalbumin-immunoreactive expression in the rat. J Psychopharmacol 21: 198-205. (Pubitemid 46280471)
2. Adams BW, Moghaddam B (2001). Effect of clozapine, haloperidol, or M100907 on phencyclidine-activated glutamate efflux in the prefrontal cortex. Biol Psychiatry 50: 750-757. (Pubitemid 33086762)
3. Amargós-Bosch M, López-Gil X, Artigas F, Adell A (2006). Clozapine and olanzapine, but not haloperidol, suppress serotonin efflux in the medial prefrontal cortex elicited by phencyclidine and ketamine. Int J Neuropsychopharmacol 9: 565-573. (Pubitemid 44607209)
4. Bilder RM, Lipschutz-Broch L, Reiter G, Geisler SH, Mayerhoff DI, Lieberman JA (1992). Intellectual deficits in first-episode schizophrenia: evidence for progressive deterioration. Schizophr Bull 18: 437-448.
5. Buchanan RW, Keefe RS, Umbricht D, Green MF, Laughren T, Marder SR (2010). The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later? Schizophr Bull 37: 1209-1217.
6. Burnet PW, Eastwood SL, Harrison PJ (1996). 5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacology 15: 442-455. (Pubitemid 26389868)
7. Burnet PW, Eastwood SL, Harrison PJ (1997). [3H]WAY-100635 for 5-HT1A receptor autoradiography in human brain: a comparison with [3H]8-OH-DPAT and demonstration of increased binding in the frontal cortex in schizophrenia. Neurochem Int 30: 565-574. (Pubitemid 27187227)
8. Choi YK, Snigdha S, Shahid M, Neill JC, Tarazi FI (2009). Subchronic effects of phencyclidine on dopamine and serotonin receptors: implications for schizophrenia. J Mol Neurosci 38: 227-235.
9. Cochran SM, Kennedy M, McKerchar CE, Steward LJ, Pratt JA, Morris BJ (2003). Induction of metabolic hypofunction and neurochemical deficits after chronic intermittent exposure to phencyclidine: differential modulation by antipsychotic drugs. Neuropsychopharmacology 28: 265-275.
10. Coyle JT (2006). Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol 26: 365-384.
11. Enomoto T, Ishibashi T, Tokuda K, Ishiyama T, Toma S, Ito A (2008). Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze tests in rats. Behav Brain Res 186: 197-207. (Pubitemid 350122756)
12. Etou K, Kuroki T, Kawahara T, Yonezawa Y, Tashiro N, Uchimura H (1998). Ceruletide inhibits phencyclidine-induced dopamine and serotonin release in rat prefrontal cortex. Pharmacol Biochem Behav 61: 427-434. (Pubitemid 28511223)
13. Feighner JP, Boyer WF (1989). Serotonin-1A anxiolytics: an overview. Psychopathology 22(Suppl 1): 21-26. (Pubitemid 19104666)
14. Gardell LR, Vanover KE, Pounds L, Johnson RW, Barido R, Anderson GT et al. (2007). ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models. J Pharmacol Exp Ther 322: 862-870. (Pubitemid 47105818)
15. Goldman-Rakic PS, Selemon LD (1997). Functional and anatomical aspects of prefrontal pathology in schizophrenia. Schizophr Bull 23: 437-458. (Pubitemid 27427984)
16. Grayson BI, Idris NF, Neill JC (2007). Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat. Behav Brain Res 184: 31-38. (Pubitemid 47404650)
17. Gunduz-Bruce H (2009). The acute effects of NMDA antagonism: from the rodent to the human brain. Brain Res Rev 60: 279-286.
18. Gurevich EV, Joyce JN (1997). Alterations in the cortical serotonergic system in schizophrenia: a postmortem study. Biol Psychiatry 42: 529-545. (Pubitemid 27425471)
19. Hagger C, Buckley P, Kenny JT, Friedman L, Ubogy D, Meltzer HY (1993). Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry 34: 702-712. (Pubitemid 23354783)
20. Hagiwara H, Fujita Y, Ishima T, Kunitachi S, Shirayama Y, Iyo M et al. (2008). Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antipsychotic drug perospirone: role of serotonin 5-HT1A receptors. Eur Neuropsychopharmacol 18: 448-454.
21. Hamik A, Oksenberg D, Fischette C, Peroutka SJ (1990). Analysis of tandospirone (SM-3997) interactions with neurotransmitter receptor binding sites. Biol Psychiatry 28: 99-109. (Pubitemid 20226391)
22. Harvey PD, Ogasa M, Cucchiaro J, Loebel A, Keefe RS (2011). Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone. Schizophr Res 127: 188-194.
23. Hashimoto K, Fujita Y, Shimizu E, Iyo M (2005). Phencyclidineinduced cognitive deficits in mice are improved by subsequent sub-chronic administration of clozapine, but not haloperidol. Eur J Pharmacol 519: 114-117. (Pubitemid 43181173)
24. Hashimoto T, Nishino N, Nakai H, Tanaka C (1991). Increase in serotonin 5-HT1A receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia. Life Sci 48: 355-363.
25. Horiguchi M, Huang M, Meltzer HY (2011a). Interaction of mGlu(2/3) agonism with clozapine and lurasidone to restore novel object recognition in subchronic phencyclidine-treated rats. Psychopharmacology (Berl) 217: 13-24.
26. Horiguchi M, Huang M, Meltzer HY (2011b). The role of 5-HT7 receptors in the phencyclidine (PCP)-induced novel object recognition (NOR) deficit in rats. J Pharmacol Exp Ther 338: 605-614.
27. Horiguchi M, Meltzer HY (2012). The role of 5-HT1A receptors in phencyclidine (PCP)-induced novel object recognition (NOR) deficit in rats. Psychopharmacology (Berl) 221: 205-215.
28. Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O'Laughlin IA, Meltzer HY (2001). 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 76: 1521-1531. (Pubitemid 32198256)
29. Ichikawa J, Li Z, Dai J, Meltzer HY (2002). Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Res 956: 349-357. (Pubitemid 35351402)
30. Ishibashi T, Horisawa T, Tokuda K, Ishiyama T, Ogasa M, Tagashira R et al. (2010). Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-HT7 and 5-HT1A receptor activity. J Pharmacol Exp Ther 334: 171-181.
31. Ishiyama T, Tokuda K, Ishibashi T, Ito A, Toma S, Ohno Y (2007). Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test. Eur J Pharmacol 572: 160-170. (Pubitemid 47429645)
32. Javitt DC, Zukin SR (1991). Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148: 1301-1308.
33. Jenkins TA, Harte MK, McKibben CE, Elliott JJ, Reynolds GP (2008). Disturbances in social interaction occur along with pathophysiological deficits following sub-chronic phencyclidine administration in the rat. Behav Brain Res 194: 230-235.
34. Kasper S, Tauscher J, Willeit M, Stamenkovic M, Neumeister A, Küfferle B et al. (2002). Receptor and transporter imaging studies in schizophrenia, depression, bulimia and Tourette0s disorderFimplications for psychopharmacology. World J Biol Psychiatry 3: 133-146.
35. Kaur T, Cadenhead KS (2010). Treatment implications of the schizophrenia prodrome. Curr Top Behav Neurosci 4: 97-121.
36. Keefe RSE, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM et al. (2007). Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry 64: 633-647. (Pubitemid 46878665)
37. Klosterkötter J, Hellmich M, Steinmeyer EM, Schultze-Lutter F (2001). Diagnosing schizophrenia in the initial prodromal phase. Arch Gen Psychiatry 58: 158-164. (Pubitemid 32142753)
38. Krystal JH, D'Souza DC, Petrakis IL, Belger A, Berman RM, Charney DS et al. (1999). NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders. Harv Rev Psychiatry 7: 125-143. (Pubitemid 30240826)
39. Larson MK, Walker EF, Compton MT (2010). Early signs, diagnosis and therapeutics of the prodromal phase of schizophrenia and related psychotic disorders. Expert Rev Neurother 10: 1347-1359.
40. Lee C, McGlashan TH, Woods SW (2005). Prevention of schizophrenia: can it be achieved? CNS Drugs 19: 193-206. (Pubitemid 40460660)
41. Lieberman JA, Fenton WS (2000). Delayed detection of psychosis: causes, consequences, and effect on public health. Am J Psychiatry 157: 1727-1730.
42. Martin P, Carlsson ML, Hjorth S (1998). Systemic PCP treatment elevates brain extracellular 5-HT: a microdialysis study in awake rats. Neuroreport 9: 2985-2988. (Pubitemid 28555632)
43. Massana G, Salgado-Pineda P, Junqué C, Pérez M, Baeza I, Pons A et al. (2005). Volume changes in gray matter in first-episode neuroleptic-naive schizophrenic patients treated with risperidone. J Clin Psychopharmacol 25: 111-117. (Pubitemid 40395088)
44. Maurel-Remy S, Bervoets K, Millan MJ (1995). Blockade of phencyclidine-induced hyperlocomotion by clozapine and MDL 100,907 in rats reflects antagonism of 5-HT2A receptors. Eur J Pharmacol 280: R9-R11.
45. McGlashan TH, Fenton WS (1993). Subtype progression and pathophysiologic deterioration in early schizophrenia. Schizophr Bull 19: 71-84. (Pubitemid 23073556)
46. McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW et al. (2006). Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 163: 790-799. (Pubitemid 44464525)
47. McGorry PD, Killackey E, Yung A (2008). Early intervention in psychosis: concepts, evidence and future directions. World Psychiatry 7: 148-156.
48. McKibben CE, Jenkins TA, Adams HN, Harte MK, Reynolds GP (2010). Effect of pretreatment with risperidone on phencyclidine- induced disruptions in object recognition memory and prefrontal cortex parvalbumin immunoreactivity in the rat. Behav Brain Res 208: 132-136.
49. Meltzer HY (1999). The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 21(2 Suppl): 106S-115S. (Pubitemid 29396478)
50. Meltzer HY, Horiguchi M, Massey BW (2011). The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment. Psychopharmacology (Berl) 213: 289-305.
51. Meltzer HY, McGurk SR (1999). The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25: 233-255. (Pubitemid 29272503)
52. Meyer JM, Loebel AD, Schweizer E (2009). Lurasidone: a new drug in development for schizophrenia. Expert Opin Investig Drugs 18: 1715-1726.
53. Millan MJ, Brocco M, Gobert A, Joly F, Bervoets K, Rivet J et al. (1999). Contrasting mechanisms of action and sensitivity to antipsychotics of phencyclidine versus amphetamine: importance of nucleus accumbens 5-HT2A sites for PCP-induced locomotion in the rat. Eur J Neurosci 11: 4419-4432. (Pubitemid 30009274)
54. Molina V, Reig S, Sanz J, Palomo T, Benito C, Sánchez J et al. (2005). Increase in gray matter and decrease in white matter volumes in the cortex during treatment with atypical neuroleptics in schizophrenia. Schizophr Res 80: 61-71. (Pubitemid 41587464)
55. Nabeshima T, Yamaguchi K, Yamada K, Hiramatsu M, Kuwabara Y, Furukawa H et al. (1984). Sex-dependent differences in the pharmacological actions and pharmacokinetics of phencyclidine in rats. Eur J Pharmacol 97: 217-227. (Pubitemid 14183531)
56. Nagai T, Murai R, Matsui K, Kamei H, Noda Y, Furukawa H et al. (2009). Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors. Psychopharmacology (Berl) 202: 315-328.
57. Neill JC, Barnes S, Cook S, Grayson B, Idris NF, McLean SL et al. (2010). Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism. Pharmacol Ther 128: 419-432.
58. Phillips LJ, Nelson B, Yuen HP, Francey SM, Simmons M, Stanford C et al. (2009). Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: study design and baseline characteristics. Aust N Z J Psychiatry 43: 818-829.
59. Piontkewitz Y, Arad M, Weiner I (2012). Tracing the development of psychosis and its prevention: what can be learned from animal models. Neuropharmacology 62: 1273-1289.
60. Richtand NM, Taylor B, Welge JA, Ahlbrand R, Ostrander MM, Burr J et al. (2006). Risperidone pretreatment prevents elevated locomotor activity following neonatal hippocampal lesions. Neuropsychopharmacology 31: 77-89. (Pubitemid 43250943)
61. Ruhrmann S, Schultze-Lutter F, Maier W, Klosterkötter J (2005). Pharmacological intervention in the initial prodromal phase of psychosis. Eur Psychiatry 20: 1-6. (Pubitemid 40092385)
62. Salokangas RK, McGlashan TH (2008). Early detection and intervention of psychosis. A review. Nord J Psychiatry 62: 92-105. (Pubitemid 351943593)
63. Saykin AJ, Gur RC, Gur RE, Mozley PD, Mozley LH, Resnick SM et al. (1991). Neuropsychological function in schizophrenia. Selective impairment in memory and learning. Arch Gen Psychiatry 48: 618-624.
64. Simpson MD, Lubman DI, Slater P, Deakin JF (1996). Autoradiography with [3H]8-OH-DPAT reveals increases in 5-HT(1A) receptors in ventral prefrontal cortex in schizophrenia. Biol Psychiatry 39: 919-928.
65. Snigdha S, Horiguchi M, Huang M, Li Z, Shahid M, Neill JC et al. (2010). Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical antipsychotic drugs and pimavanserin (ACP 103), a 5-hydroxytryptamine(2A) receptor inverse agonist. J Pharmacol Exp Ther 332: 622-631.
66. Sumiyoshi T, Matsui M, Yamashita I, Nohara S, Uehara T, Kurachi M et al. (2000). Effect of adjunctive treatment with serotonin-1A agonist tandospirone on memory functions in schizophrenia. J Clin Psychopharmacol 20: 386-388. (Pubitemid 30318373)
67. Sumiyoshi T, Matsui M, Nohara S, Yamashita I, Kurachi M, Sumiyoshi C et al. (2001a). Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am J Psychiatry 158: 1722-1725. (Pubitemid 32923670)
68. Sumiyoshi T, Matsui M, Yamashita I, Nohara S, Kurachi M, Uehara T et al. (2001b). The effect of tandospirone, a serotonin(1A) agonist, on memory function in schizophrenia. Biol Psychiatry 49: 861-868. (Pubitemid 32436390)
69. Sumiyoshi T, Stockmeier CA, Overholser JC, Dilley GE, Meltzer HY (1996). Serotonin1A receptors are increased in postmortem prefrontal cortex in schizophrenia. Brain Res 708: 209-214.
70. Sutcliffe JS, Marshall KM, Neill JC (2007). Influence of gender on working and spatial memory in the novel object recognition task in the rat. Behav Brain Res 177: 117-125. (Pubitemid 46054189)
71. Tanibuchi Y, Fujita Y, Kohno M, Ishima T, Takatsu Y, Iyo M et al. (2009). Effects of quetiapine on phencyclidine-induced cognitive deficits in mice: a possible role of alpha1-adrenoceptors. Eur Neuropsychopharmacol 19: 861-867.
72. Tauscher J, Kapur S, Verhoeff NP, Hussey DF, Daskalakis ZJ, Tauscher-Wisniewski S et al. (2002). Brain serotonin 5-HT(1A) receptor binding in schizophrenia measured by positron emission tomography and [11C]WAY-100635. Arch Gen Psychiatry 59: 514-520. (Pubitemid 34602933)
73. Vanover KE, Weiner DM, Makhay M, Veinbergs I, Gardell LR, Lameh J et al. (2006). Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1- methylpiperidin-4-yl)-N0-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist. J Pharmacol Exp Ther 317: 910-918.
74. Wang HD, Deutch AY (2008). Dopamine depletion of the prefrontal cortex induces dendritic spine loss: reversal by atypical antipsychotic drug treatment. Neuropsychopharmacology 33: 1276-1286. (Pubitemid 351521724)
75. Winters BD, Saksida LM, Bussey TJ (2010). Implications of animal object memory research for human amnesia. Neuropsychologia 48: 2251-2261.
76. Woodward ND, Purdon SE, Meltzer HY, Zald DH (2005). A metaanalysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 8: 457-472. (Pubitemid 41002500)